Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)

BMS Reinforces Leadership in oHCM with New Camzyos Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26) ...
Healio

‘Patients feel better’: New hope for obstructive hypertrophic cardiomyopathy

Please provide your email address to receive an email when new articles are posted on . Hypertrophic cardiomyopathy is the most common monogenic CV disorder, yet perhaps the most frequently ...
Seeking Alpha

Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced positive topline results from SEQUOIA-HCM (Safety, Efficacy, and Quantitative ...
Healio

Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy

Please provide your email address to receive an email when new articles are posted on . Hypertrophic cardiomyopathy is the most common genetic heart disease, with prevalence estimates from one in 200 ...

Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo

New Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten)SOUTH SAN FRANCISCO, ...
Monthly Prescribing Reference

Aficamten Under Review for Obstructive Hypertrophic Cardiomyopathy

Treatment with aficamten significantly improved exercise capacity compared with placebo. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for aficamten for ...
Nasdaq

Cytokinetics Announces SEQUOIA-HCM Analysis Results Highlighting Aficamten's Efficacy and Disparities in Hypertrophic Cardiomyopathy Outcomes Across Patient Demographics

Cytokinetics, Incorporated announced findings from two analyses of the SEQUOIA-HCM trial that studied the effects of aficamten on patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM ...
TCTMD

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

WASHINGTON, DC (UPDATED)—Among patients with obstructive hypertrophic cardiomyopathy (HCM) who are candidates for surgical or interventional septal reduction therapy (SRT) despite being on maximally ...
Nasdaq

Cytokinetics to Showcase Positive Aficamten Results for Obstructive Hypertrophic Cardiomyopathy at European Society of Cardiology Congress 2025

Cytokinetics, Incorporated announced five presentations related to aficamten at the upcoming European Society of Cardiology Congress 2025 in Madrid, highlighting positive topline results from the ...
Medscape

Positive Topline Data for Aficamten in Obstructive HCM

The investigational, next-generation cardiac myosin inhibitor aficamten (previously CK-274, Cytokinetics) continues to show promise as a potential treatment for hypertrophic cardiomyopathy (HCM).
Business Wire

Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 VALOR-HCM study, which showed the addition of mavacamten, an investigational, first-in-class ...
Medscape

Myosin Inhibitor Aficamten Boosts QoL, Eases Symptoms in Obstructive HCM

Patients with obstructive hypertrophic cardiomyopathy (HCM) who took the myosin inhibitor aficamten (Cytokinetics) showed major improvements in heart failure (HF) symptoms, functional capacity, ...